tbuckley/cabot-search huggingface dataset:
<i>mda-7/IL-24</i> Mediates Cancer Cell–Specific Death via Regulation of miR-221 and the Beclin-1 Axis
Authors: Anjan K. Pradhan, Sarmistha Talukdar, Praveen Bhoopathi, Xue-Ning Shen, Luni Emdad, Swadesh K. Das, Devanand Sarkar, Paul B. Fisher
Journal: Cancer Research (2016)

Abstract Melanoma differentiation-associated gene-7/IL-24 (mda-7/IL-24) displays broad-spectrum anticancer activity in vitro, in vivo in preclinical animal models, and in a phase I/II clinical trial in patients with advanced cancers without harming normal cells or tissues. Here we demonstrate that mda-7/IL-24 regulates a specific subset of miRNAs, including cancer-associated miR-221. Either ectopic expression of mda-7/IL-24 or treatment with recombinant His-MDA-7 protein resulted in downregulation of miR-221 and upregulation of p27 and PUMA in a panel of cancer cells, culminating in cell death. Mda-7/IL-24–induced cancer cell death was dependent on reactive oxygen species induction and was rescued by overexpression of miR-221. Beclin-1 was identified as a new transcriptional target of miR-221, and mda-7/IL-24 regulated autophagy through a miR-221/beclin-1 feedback loop. In a human breast cancer xenograft model, miR-221–overexpressing MDA-MB-231 clones were more aggressive and resistant to mda-7/IL-24–mediated cell death than parental clones. This is the first demonstration that mda-7/IL-24 directly regulates miRNA expression in cancer cells and highlights the novelty of the mda-7/IL-24–miR-221–beclin-1 loop in mediating cancer cell–specific death. Cancer Res; 77(4); 949–59. ©2016 AACR.
Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)
Authors: Jianxiang Wang, Yingchang Mi, Bin Jiang, Xiequn Chen, Chunyan Ji, Yan Li, Xielan Zhao, Yongrong Lai, Yu Hu, Aiping Tang, Ting Liu, Jie Jin, Junmin Li, Linhua Yang, Jianyong Li, Fanyi Meng
Journal: Blood (2015)
Nucleophosmin-1 Interacts with CCAAT Enhancer Binding Protein Alpha (C/EBPα) to Facilitate Granulocyte Maturation: Implications in MDS and AML.
Authors: Arati Khanna-Gupta, Jian Chen, Matthew Silver, Hong Sun, Nirmalee Abayasekara, Stephanie Halene, Paolo Sportoletti, Pier Paolo Pandolfi, Nancy Berliner
Journal: Blood (2009)
Thermal Pain and Pain Anticipation Induce a Decrease in Microvascular Perfusion in Sickle Cell and Normal Subjects
Authors: Maha Khaleel, Mammen Puliyel, John Sunwoo, Payal Shah, Roberta Miyeko Kato, Patjanaporn Chalacheva, Wanwara Thuptimdang, John C Wood, Jennie Tsao, Lonnie Zeltzer, Richard Sposto, Michael Khoo, Thomas D. Coates
Journal: Blood (2015)
Vitamin K2 Induces Autophagy and Apoptosis Simultaneously in Leukemia Cells and Bcl-2 Expression Level Determines the Phenotype of Their Cell Death.
Authors: Keisuke Miyazawa, Tomohisa Yokoyama, Munekazu Naito, Juri Toyotake, Testuzo Tauchi, Masahiro Itoh, Akira Yuo, Yasuko Kondo, Seiji Kondo, Kazuma Ohyashiki
Journal: Blood (2007)
The effects of substance P fragments on breast cancer cells.
Authors: E. Oz, E. Aydemir, A. F. Korcum, K. Fiskin
Journal: Journal of Clinical Oncology (2011)

295 Background: Substance P (SP), a neuropeptide, is known to induce tumor cell proliferation. In contrast with intact peptide, the fragments of SP are suggested to inhibit the growth of various cancer cells. The aim of the present study was to determine cytotoxic effects of physiological fragments of SP either alone or in combination with radiotherapy on mouse breast cancer cells. Methods: In this study, we tested the physiological fragments of SP such as SP (4-11), SP (6-11) and SP (1-7). Dose-response and time-course studies were carried out with various concentrations (100-0.001 nM) of SP fragments and the intact peptide. 4T1 mouse breast cancer cell lines were used in this study. The cytotoxic effect of SP fragments alone or in combination with radiotherapy was determined via WST-1 assay. Changes in substance P amounts in cells and in mediums determined by SP EIA kit. Results: SP(4-11) and SP(6-11), but not SP(1-7), inhibited the proliferation of breast cancer cells and potentiated antitumor effects of radiotherapy. Moreover, the intact peptide alone did not alter the proliferation rate of 4T1 cells and the cytotoxic effects of the fragments were not inhibited by SP. Conclusions: These results demonstrate that combined treatment with 2 fragments of SP (4-11 and 6-11) and radiotherapy induce cytotoxic effects. These data may provide the basis for a strategy, in which it is possible to use SP fragments and radiotherapy together to improve the efficiency of the independent therapies.
Regulated Expression of Activated Notch 1 during Embryonic Stem Cell Differentiation Preserves Multipotential Progenitors and Promotes Erythroid Cell Fate.
Authors: Uma Ganapati, Lynne A. Bui, Maureen Lynch, Milana Dolezal, Hongying Tina Tan, Sven deVos, Judith C. Gasson
Journal: Blood (2004)
Associations between county-level general surgeon (GS) and gastroenterologist (GA) density and outcomes for hepatobiliary cancer (HBC).
Authors: Trevor C. Tsang, Winson Y. Cheung
Journal: Journal of Clinical Oncology (2012)

292 Background: Surgical resection is the mainstay of treatment for early, localized HBC. Prior studies consistently show an association between procedure volumes and cancer outcomes, but the impact of surgeon and physician density is unclear. Our aims were to 1) examine the effects of GS and GA density on HBC mortality and 2) compare the relative importance of GS versus GA density on HBC outcomes. Methods: Using county-level data from the Area Resource File, US Census, and National Cancer Institute, we developed both multivariate linear and logistic regression models to determine the effect of GS and GA density on overall HBC mortality between 2002 and 2006, while controlling for cancer incidence, county demographics and socioeconomic factors. Results: In total, 793 counties were analyzed: mean HBC incidence and mortality were 5.89 and 5.34 per 100,000 persons, respectively; 77% were metropolitan; mean GS and GA densities were 10.6 and 3.5 per 100,000 people, respectively. When compared to counties with no GS, those with at least one had a statistically significant decrease in HBC-specific mortality (beta coefficient -.115; p=.001). In contrast, when compared to counties with no GA, those with at least one showed a trend towards lower mortality (beta coefficient -.0677; p=.065). Increasing the county-level density of GS and GA improved outcomes, but increases beyond 10 GS or 4 GA per 100,000 people did not continue to result in significant reductions in HBC mortality; rather, these showed an increase in HBC mortality. Conclusions: Reductions in HBC mortality are more strongly influenced by increasing GS than GA density. There appears to be a ceiling effect at which point increasing GS and GA density does not appear to result in improvements in HBC outcomes. A strategy of allocating healthcare resources and distributing the workforce across counties will optimize outcomes at the population-level.
C/EBPα:AP-1 Leucine Zipper Heterodimers Bind Novel DNA Elements, Activate the PU.1 Promoter, and Direct Monocyte Lineage Commitment More Potently Than C/EBPα Homodimers or AP-1.
Authors: Alan D. Friedman, Dong Hong Cai, Dehua Wang, Jeffrey Keefer, Christine Yeamans, Kortney Hensley
Journal: Blood (2007)
High-dose metformin (420 mg/kg daily p.o.) increases insulin sensitivity but does not affect neointimal thickness in the rat carotid balloon injury model of restenosis
Authors: June Guo, Troy J. Pereira, Prasad Dalvi, Lucy Shu Nga Yeung, Nathan Swain, Danna M. Breen, Loretta Lam, Vernon W. Dolinsky, Adria Giacca
Journal: Metabolism (2016)
Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma
Authors: Sampath Ramachandiran, Xiangxue Guo, Laurent Garderet, Souhila Ikhlef, Jean El-cheikh, Michael R Weil, Andrew N Young, Mahir Bagirov, Sagar Lonial, Zhengjia Chen, Jeanne Kowalsky, Yuhong Du, Hanna J. Khoury, Susan Sunay, Jonathan L. Kaufman, Lawrence H. Boise, Michael Rossi, Leon Bernal-Mizrachi
Journal: Blood (2011)
Mast Cell Activation Contributes to Neurogenic Inflammation and Pain in Sickle Cell Disease
Authors: Lucile Vincent, Julia Nguyen, Derek Vang, Oludare B Taiwo, Kathryn Luk, Michael Ansonoff, Marna Ericson, Donald Simone, John E. Pintar, Robert P Hebbel, Kalpna Gupta
Journal: Blood (2012)
Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).
Authors: Leslie Andritsos, Mehdi Hamadani, Nyla A. Heerema, Don Benson, Craig C. Hofmeister, William Blum, Joseph Flynn, Jeffrey Alan Jones, Patrick Elder, Thomas S. Lin, Gerard Lozanski, John C. Byrd, Steven Devine
Journal: Blood (2008)
Endothelial Cells Promote Endogenous Thymic Regeneration after Injury Via BMP4 Signaling
Authors: Tobias Wertheimer, Christopher Carl Kloss, Enrico Velardi, Christian Brede, Michael Ginsberg, Fabiana M Kreines, Johannes L. Zakrzewski, Andrea Z. Tuckett, Jennifer Jia-ying Tsai, Odette M Smith, Emily R Levy, Andreas Beilhack, Shahin Rafii, Jason M. Butler, Marcel R.M. van den Brink, Jarrod A Dudakov
Journal: Blood (2014)
Cyclosporine A and Mycophenolate Mofetil Versus Cyclosporine A and Methotrexate for Graft Versus Host Disease Prophylaxis after Stem Cell Transplantation from HLA-Identical Siblings.
Authors: Frank Neumann, Thorsten Graef, Christoph Tapprich, Matthias Vaupel, Ulrich Steidl, Ulrich Germing, Roland Fenk, Rainer Haas, Guido Kobbe
Journal: Blood (2004)
The SMAC Mimetic Lcl-161 Demonstrates Anti-Tumor Activity As a Single Agent and Decreases the Apoptotic Threshold of Chemotherapy Agents in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models
Authors: Kyle Runckel, Cory Mavis, Joseph Skitzki, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2012)
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros Lekakis, David Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan Oluwole, Tanya Siddiqi, Yi Lin, John Timmerman, Patrick J. Stiff, Jonathan Friedberg, Ian Flinn, Andre Goy, Mitchell Smith, Abhinav Deol, Umar Farooq, Peter McSweeney, Javier Munoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chavez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Patrick Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff S. Aycock, Meg Elias, Jeff Wiezorek, William Y. Go
Journal: Blood (2016)
A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy.
Authors: A. C. Ferrari, M. N. Stein, J. J. Alumkal, A. Gomez-Pinillos, D. D. Catamero, T. M. Mayer, F. Collins, T. M. Beer, R. S. DiPaola
Journal: Journal of Clinical Oncology (2011)

156 Background: Aberrant expression and function of the androgen receptor (AR) is determinant of CRPC progression. We previously demonstrated that the histone-deacetylase inhibitor panobinostat (PAN) decreased AR levels and reversed resistance of androgen-independent AI-LNCaP and Rv1 cells to the antiandrogen bicalutamide (Bic). We designed a ph-I/II study to determine whether PAN would restore the sensitivity to Bic in CRPC patients (pts). We report the ph-I results evaluating safety and maximum tolerated dose (MTD) of Bic combined with oral, intermittent PAN. Methods: Men with CRPC and limited bone metastasis, ECOG PS 0-2, PSA&gt;2 ng/ml (or &lt;2 + new metastases), adequate organ function and QTc&lt;450 ms progressing on at least two prior hormones including antiandrogens were assigned each to one of 3 cohorts (C) for treatment with Bic 50 mg PO daily with oral PAN at 3 dose levels: C1, 20 mg tri-wkly (60 mg/wk) 2 of 3 wks; C2: 30 mg tri-wkly (90mg/wk) 2 of 3 wks, 40 mg PO tri-wkly (120mg/wk) 3 of 3 wks. Cycles (Cy) repeated every 21 days. Minimum treatment was 3 wks. Treatment could continue if clinical benefit. DLT were: grade (G) 3-4 febrile neutropenia &gt;5 days and/or hospitalization; G3 thrombocytopenia with bleeding; QTcF&gt;500 ms any G4 except nausea, vomiting, or diarrhea. Results: Nine men, median (m) 65 yrs were treated in cohorts of three. mPSA at entry 9.26 ng/mL (IQR:8.24), mCy number, 6 (IQR: 5). MTD was not reached. All experienced some grade of toxicity attributable to PAN. Toxicity: no G4, only G3 was thrombocytopenia without bleeding in 3 pts (1 in C1, 2 in C3) that resolved spontaneously and controlled by dose reduction; G2: thrombocytopenia in 3, fatigue 2, high cholesterol 2, hypothyroidism 2; G1 thrombocytopenia in 2, fatigue 3, dyspepsia 3, anorexia 2. PSA decline ≥50% was achieved in 2 pts, stable PSA in 3 pts. Ph-II recommended PAN doses: Arm A: 40 mg tri-wkly (120 mg/wk) 2 of 3 wks; Arm B: 20 mg tri-wkly (60 mg/wk) 2 of 3wks with Bic 50 mg/daily. Conclusions: Oral, intermittent PAN in combination with daily Bic is well tolerated in CRPC pts progressing on second line hormones and shows promising PSA responses suggesting anti-AR activity. Ph-II is ongoing. [Table: see text]
Use of the slope of the DVH curve for predicting late rectal toxicity in IMRT for patients with localized prostate cancer.
Authors: Gilles Crehange, Paul M Walker, Mélanie Gauthier, Céline Mirjolet-Didelot, Aurelie Petitfils, Etienne Martin, Jérôme Chamois, Cedric Khoury, Philippe Maingon
Journal: Journal of Clinical Oncology (2012)

230 Background: Dose volume specific endpoints (DVSE) have been demonstrated to be reliable and reproducible for predicting late toxicity with conformal 3D-RT. New highly sophisticated delivery techniques such as IGRT or IMRT or combined IG-IMRT can spare rectum more efficiently while substantially increasing the delivered dose to the prostate. The purpose of this study is to investigate whether the slope of the DVH curve could predict late rectal toxicity more accurately than DVSE in prostate cancer (PCa) patients. Methods: Charts from164 men with complete DVH data who had a localized PCa were treated with exclusive IG-IMRT. The rectum was defined as a cylindrical structure around the outer rectal wall and contoured from the ischial tuberosities to the rectosigmoid junction. A set of DVSE were registered (V75, V70, V60). Four distinct DVH groupings were defined for each DVSE: [0–5%], ]5–10%], ]10–15%] and ]15–20%]. In parallel, we decided to calculate the slope of the DVH curves encompassing the 3 DVSE: 60Gy, 70Gy and 75Gy. The median dose prescribed to the prostate was 78Gy (min. 74Gy – max. 78Gy). Late toxicity was retrospectively scored according to the CTC v.3.0 morbidity grading scales. Univariate analysis using a logistic regression was performed to determine the relationship between DVSE, the slope 60-75Gy and the appearance of any late rectal toxicity (grade ≥ 1). Results: With a median follow-up of 38.3 months [5.25 – 87.3], the rates of grade (G) 1, G2 gastrointestinal toxicity were 20.4%, 2.4%. No grade 3 or 4 occurred. For the rectum, the average Dmean, D98, V75, V70 and V60 were 39.9 Gy [25.7–61.1], 8.9Gy [1.0–38.8], 1.1Gy [0.0–33.3], 6.0 Gy [0.0–44.0] and 19.0 Gy [1.0–70.0]. DVH groupings for V75, V70 and V60 were not predictive of any G≥1 late rectal toxicity (p= 0.836, p= 0.580 and p= 0.152, respectively). The slope 60-75Gy was significantly correlated with late rectal toxicity ≥ G1 (OR= 0.55, [CI95%: 0.33–0.92], p= 0.024). Conclusions: DVSE could be irrelevant with IG-IMRT, thus jeopardizing the clinical benefit of dose escalation. The slope of the curve predicts more accurately late toxicity when attempting to optimize dose distribution.
Shared decision making in patients with low risk chest pain: prospective randomized pragmatic trial
Authors: Erik P Hess, Judd E Hollander, Jason T Schaffer, Jeffrey A Kline, Carlos A Torres, Deborah B Diercks, Russell Jones, Kelly P Owen, Zachary F Meisel, Michel Demers, Annie Leblanc, Nilay D Shah, Jonathan Inselman, Jeph Herrin, Ana Castaneda-Guarderas, Victor M Montori
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To compare the effectiveness of shared decision making with usual care in choice of admission for observation and further cardiac testing or for referral for outpatient evaluation in patients with possible acute coronary syndrome. <b>Design</b>&nbsp;Multicenter pragmatic parallel randomized controlled trial. <b>Setting</b>&nbsp;Six emergency departments in the United States. <b>Participants</b>&nbsp;898 adults (aged &gt;17 years) with a primary complaint of chest pain who were being considered for admission to an observation unit for cardiac testing (451 were allocated to the decision aid and 447 to usual care), and 361 emergency clinicians (emergency physicians, nurse practitioners, and physician assistants) caring for patients with chest pain. <b>Interventions</b>&nbsp;Patients were randomly assigned (1:1) by an electronic, web based system to shared decision making facilitated by a decision aid or to usual care. The primary outcome, selected by patient and caregiver advisers, was patient knowledge of their risk for acute coronary syndrome and options for care; secondary outcomes were involvement in the decision to be admitted, proportion of patients admitted for cardiac testing, and the 30 day rate of major adverse cardiac events. <b>Results</b>&nbsp;Compared with the usual care arm, patients in the decision aid arm had greater knowledge of their risk for acute coronary syndrome and options for care (questions correct: decision aid, 4.2 <i>v</i> usual care, 3.6; mean difference 0.66, 95% confidence interval 0.46 to 0.86), were more involved in the decision (observing patient involvement scores: decision aid, 18.3 <i>v</i> usual care, 7.9; 10.3, 9.1 to 11.5), and less frequently decided with their clinician to be admitted for cardiac testing (decision aid, 37% <i>v</i> usual care, 52%; absolute difference 15%; P&lt;0.001). There were no major adverse cardiac events due to the intervention. <b>Conclusions</b>&nbsp;Use of a decision aid in patients at low risk for acute coronary syndrome increased patient knowledge about their risk, increased engagement, and safely decreased the rate of admission to an observation unit for cardiac testing. <b>Trial registration</b>&nbsp;ClinicalTrials.gov NCT01969240.
The Immature Platelet Fraction in HIV Patients with Thrombocytopenia.
Authors: Brian T. Garibaldi, Rupal B. Malani, Hsin-Chieh Yeh, Deborah Michell, Evan J. Lipson, Mosi K. Bennett, Alison R. Moliterno2, Michael A. McDevitt2, Thomas S. Kickler2
Journal: Blood (2007)
Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy.
Authors: W. F. Symmans, F. Andre, M. C. Liu, J. Delacruz, F. Peintinger, S. Borstnar, H. Wang, P. Regitnig, M. Ota, S. Seevaratnam, S. Delaloge, C. Hatzis
Journal: Journal of Clinical Oncology (2011)

1030 Background: The adjuvant chemotherapy +/− endocrine survival (ACES) predictor is a microarray-based genomic algorithm that combines signatures for sensitivity to endocrine therapy (SET), chemo-resistance, and chemo-sensitivity to provide a binary prediction of sensitivity or insensitivity to adjuvant chemotherapy +/− endocrine therapy (Symmans et al, SABCS, 2010). Methods:Eligible patients received ≥ 5 cycles of sequential anthracyline-taxane chemotherapy for HER2-negative cancer diagnosed ≥ 3 years ago. Sites sent de-identified frozen primary tumor samples to MDACC for gene expression profiling (Affymetrix U133A) for predictions of ACES, pCR (DLDA30), genomic grade (GGI), and intrinsic subtype (PAM50). Clinical information (from sites) and prediction results (from MDACC) were matched and analyzed at Georgetown. Distant relapse-free survival at 3 years (3yr-DRFS), and absolute risk reduction (ARR), for patients predicted to be treatment (Rx)-sensitive (versus Rx-insensitive) were evaluated with 95% confidence interval (CI). Estimated sample size: 165 patients for 80% power to detect 3yr-DRFS >80% if predicted to be Rx-sensitive, at 5% one-sided significance level. Results: Follow up ≥ 3yr was known for 101 (95%) of 106 evaluable patients (3yr-DRFS 80%) with AJCC Stage I (24%), IIA (41%), IIB (24%), or III (12%). Chemotherapy was fluorouracil, epirubicin, cyclophosphamide (FEC), followed by docetaxel in 100, or paclitaxel in 6 patients. Patients with ACES prediction of Rx-sensitive (39%) had 3yr-DRFS 90% (CI 80−99) and absolute risk reduction (ARR) 17% (CI 2−30), compared to predicted Rx-insensitive. In contrast, patients predicted to be chemo-sensitive by DLDA30 (pCR, 19%), GGI (high, 59%), or PAM50 (basal/luminal B, 30%) had 3yr-DRFS of 47% (CI 25−70), 74% (CI 63−85), and 67% (CI 51−84); and ARR of −40% (CI −64 to −15), −15% (CI −28 to 2), and −18% (CI −36 to 1), respectively (negative ARR means increased risk). Conclusions: ACES prediction of Rx-sensitive breast cancer was associated with excellent and significantly improved 3yr-DRFS, whereas three other published predictors of response had paradoxically worse DRFS.
<sup>11</sup>c-choline-PET/CT versus transrectal ultrasound-guided prostate biopsy to diagnose locally recurrent prostate cancer following radiation therapy.
Authors: A. Heidenreich, D. A. Pfister, R. Epplen, B. Brehmer
Journal: Journal of Clinical Oncology (2011)

119 Background: Radical salvage prostatectomy (SRP) represents one local secondary treatment option with curative intent in patients failing radiation therapy (RT) for localized prostate cancer (PCA). 11C-PET/CT represents an innovative imaging study to detect systemic spread of prostate cancer. However, there is only limited experience with regard to the sensitivity of C-PET/CT to detect locally recurrent PCA following radiation therapy. The purpose of our study was to analyse the sensitivity of C-PET/CT to diagnose PCA and extra- and intraprostatic extension. Methods: 45 patients with the suspicion of locally recurrent PCA underwent 12-core transrectal ultrasound- guided biopsy of the prostate, C-PET/CT, bonne scan and radical salvage prostatectomy. Findings of the imaging studies were correlated with the pathohistological findings of the prostate biopsy and the radical prostatectomy specimen. All prostatectomy specimens were proceeded according to the Stanford protocol and the number and location of intraprostatic cancer foci &gt; 5mm were correlated with the PE/CT findings. Results: The mean preoperative serum PSA was 7.8 (2–24) ng/ml; the mean biopsy Gleason Score was 5.6 (4–9). Prostate biopsy was positive in 37/45 (82.2%) patients whereas 8/45 (17.8%) had a negative biopsy despite positive PET/CT findings. PET/CT was positive in 45/45 patients. Radical prostatectomy specimens identified locally recurrent PCA in 44/45 (97.8%). One patient turned out to have pT0pN0 disease despite increasing PSA. PET/CT identified 1, 2, and &gt; 2 intraprostatic cancer foci of significant volume in 23 (51.1%), 13 (28.9%) and 9 (20%) patients, respectively. Sensitivity to detect intraprostatic, histologically proven PCA foci is 95.6% which is significantly superior to the biopsy results. There was a high correlation between the PET/CT results and the final histology of the radical prostatectomy specimens. Conclusions: Choline PET/CT is an innovative imaging to identify patients with locally recurrent PCA following radiation therapy. PET/CT is superior to prostate biopsy and we recommend a PET/CT in patients who are candidates for radical salvage prostatectomy. No significant financial relationships to disclose.
IL-10 induces a STAT3-dependent autoregulatory loop in T <sub>H</sub> 2 cells that promotes Blimp-1 restriction of cell expansion via antagonism of STAT5 target genes
Authors: Amanda C. Poholek, Dragana Jankovic, Alejandro V. Villarino, Franziska Petermann, Angela Hettinga, Dror S. Shouval, Scott B. Snapper, Susan M. Kaech, Stephen R. Brooks, Golnaz Vahedi, Alan Sher, Yuka Kanno, John J. O’Shea
Journal: Science Immunology (2016)

STAT3-mediated Blimp-1 induction in T cells antagonizes STAT5’s role in promoting cell cycle and cell survival genes.